In fact, the authors revealed that the overall incidence of adverse effects was comparable between the PD-1 and PD-L1 inhibitors (64% versus 66%, p = 0.8), but in patients treated with PD-1 inhibitors IRAEs (16% versus 11%, p = 0.07) and pneumonitis (4% versus 2%, p = 0.01) increased compared with patients who received PD-L1 inhibitors [175]. The gene discussed is PDCD1; the disease is pneumonitis.